WuXi XDC and Earendil Labs Join Forces to Innovate in Antibody-Drug Conjugate Technology WuXi XDC collaborates with Earendil Labs, leveraging AI to advance antibody-drug conjugate technology, focusing on treatment for significant medical needs.

WuXi XDC and Earendil Labs Join Forces to Innovate in Antibody-Drug Conjugate Technology #China #Shanghai #ADC_technology #WuXi_XDC #Earendil_Labs

Earendil Labs Partners with WuXi XDC to Advance ADC Technology with AI Innovations Earendil Labs collaborates with WuXi XDC to enhance next-generation antibody-drug conjugates using AI-driven technology, aiming for impactful medical advancements.

Earendil Labs Partners with WuXi XDC to Advance ADC Technology with AI Innovations #United_States #Wilmington #ADC_technology #WuXi_XDC #Earendil_Labs

Allink Biotherapeutics Successfully Raises $47 Million in Series A Extension for Clinical Advancement Allink Biotherapeutics has completed a $47 million extension round of Series A funding to advance clinical programs and innovative platforms, enhancing their ADC technology development.

Allink Biotherapeutics Successfully Raises $47 Million in Series A Extension for Clinical Advancement #Shanghai #United_States #Clinical_Trials #Allink_Biotherapeutics #ADC_technology

Ajinomoto Bio-Pharma Services Recognized at World ADC Awards for Innovative AJICAP Technology Ajinomoto Bio-Pharma Services has achieved recognition for its AJICAP technology at the World ADC Awards, highlighting advancements in biopharmaceutical development.

Ajinomoto Bio-Pharma Services Recognized at World ADC Awards for Innovative AJICAP Technology #USA #Tokyo #ADC_technology #Ajinomoto #Bio-Pharma

Mycenax and RIN Collaboration to Enhance ADC Development Through Innovative Licensing Deal Mycenax Biotech Inc. and RIN Institute forge a licensing agreement to advance antibody-drug conjugate technology, enhancing global drug solutions.

Mycenax and RIN Collaboration to Enhance ADC Development Through Innovative Licensing Deal #Taiwan #Taipei #ADC_technology #Mycenax #Rin

Tagworks Pharmaceuticals Launches Third Dose Phase 1 Trial of TGW101 for Solid Tumors Tagworks Pharmaceuticals has initiated the third dose of its Phase 1 clinical trial for TGW101, an innovative treatment for advanced solid tumors, showcasing its commitment to pioneering cancer therapies.

Tagworks Pharmaceuticals Launches Third Dose Phase 1 Trial of TGW101 for Solid Tumors #Netherlands #ADC_technology #Nijmegen #Tagworks #TGW101

Acepodia Unveils Promising Preclinical Findings for Innovative Antibody-Drug Conjugate Technology Acepodia presents exciting preclinical results for their dual-payload antibody-drug conjugate technology at the AACR Annual Meeting 2025. This innovation showcases significant potential in cancer treatment.

Acepodia Unveils Promising Preclinical Findings for Innovative Antibody-Drug Conjugate Technology #USA #Chicago #Cancer_Research #ADC_technology #Acepodia

WuXi XDC and AbTis Forge Strategic Alliance for Future ADC Advances WuXi XDC partners with AbTis to enhance next-generation ADCs through innovative technology integration, accelerating development in bioconjugates.

WuXi XDC and AbTis Forge Strategic Alliance for Future ADC Advances #China #Shanghai #ADC_technology #WuXi_XDC #AbTis

Boehringer Ingelheim Expands Cancer Treatment Portfolio through Synaffix Licensing Deal Boehringer Ingelheim boosts its oncology portfolio by licensing innovative ADC technology from Synaffix, aiming to enhance cancer treatment outcomes.

Boehringer Ingelheim Expands Cancer Treatment Portfolio through Synaffix Licensing Deal #Germany #Boehringer_Ingelheim #ADC_technology #Synaffix #Ingelheim

Elevation Oncology Collaborates with Synaffix to Enhance ADC Drug Development Elevation Oncology has secured a licensing agreement with Synaffix for innovative ADC technology to boost their drug development pipeline targeting solid tumors.

Elevation Oncology Collaborates with Synaffix to Enhance ADC Drug Development #Netherlands #Amsterdam #ADC_technology #Synaffix #Elevation_Oncology

Allink Biotherapeutics Secures $42M to Enhance Bispecific Antibody and ADC Development Allink Biotherapeutics has successfully raised $42 million in Series A funding to further develop bispecific antibodies and ADCs in global markets.

Allink Biotherapeutics Secures $42M to Enhance Bispecific Antibody and ADC Development #USA #Beijing #Allink_Biotherapeutics #Lanchi_Ventures #ADC_technology